These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 23586055

  • 1. CXCR1/CXCR2 antagonism is effective in pulmonary defense against Klebsiella pneumoniae infection.
    Wei J, Peng J, Wang B, Qu H, Wang S, Faisal A, Cheng JW, Gordon JR, Li F.
    Biomed Res Int; 2013; 2013():720975. PubMed ID: 23586055
    [Abstract] [Full Text] [Related]

  • 2. The combined CXCR1/CXCR2 antagonist CXCL8(3-74)K11R/G31P blocks neutrophil infiltration, pyrexia, and pulmonary vascular pathology in endotoxemic animals.
    Gordon JR, Li F, Zhang X, Wang W, Zhao X, Nayyar A.
    J Leukoc Biol; 2005 Dec; 78(6):1265-72. PubMed ID: 16204619
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. ELR-CXC chemokine receptor antagonism targets inflammatory responses at multiple levels.
    Zhao X, Town JR, Li F, Zhang X, Cockcroft DW, Gordon JR.
    J Immunol; 2009 Mar 01; 182(5):3213-22. PubMed ID: 19234219
    [Abstract] [Full Text] [Related]

  • 6. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
    Planagumà A, Domènech T, Pont M, Calama E, García-González V, López R, Aulí M, López M, Fonquerna S, Ramos I, de Alba J, Nueda A, Prats N, Segarra V, Miralpeix M, Lehner MD.
    Pulm Pharmacol Ther; 2015 Oct 01; 34():37-45. PubMed ID: 26271598
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2.
    Kaur M, Singh D.
    J Pharmacol Exp Ther; 2013 Oct 01; 347(1):173-80. PubMed ID: 23912333
    [Abstract] [Full Text] [Related]

  • 10. The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases.
    Russo RC, Garcia CC, Teixeira MM, Amaral FA.
    Expert Rev Clin Immunol; 2014 May 01; 10(5):593-619. PubMed ID: 24678812
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Blockade of neutrophil responses in aspiration pneumonia via ELR-CXC chemokine antagonism does not predispose to airway bacterial outgrowth.
    Zhao X, Town JR, Li F, Li W, Zhang X, Gordon JR.
    Pulm Pharmacol Ther; 2010 Feb 01; 23(1):22-8. PubMed ID: 19751843
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. CXCR2 in acute lung injury.
    Konrad FM, Reutershan J.
    Mediators Inflamm; 2012 Feb 01; 2012():740987. PubMed ID: 22719179
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets.
    Bizzarri C, Beccari AR, Bertini R, Cavicchia MR, Giorgini S, Allegretti M.
    Pharmacol Ther; 2006 Oct 01; 112(1):139-49. PubMed ID: 16720046
    [Abstract] [Full Text] [Related]

  • 18. Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2.
    Maeda DY, Peck AM, Schuler AD, Quinn MT, Kirpotina LN, Wicomb WN, Fan GH, Zebala JA.
    J Med Chem; 2014 Oct 23; 57(20):8378-97. PubMed ID: 25254640
    [Abstract] [Full Text] [Related]

  • 19. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation.
    Chapman RW, Minnicozzi M, Celly CS, Phillips JE, Kung TT, Hipkin RW, Fan X, Rindgen D, Deno G, Bond R, Gonsiorek W, Billah MM, Fine JS, Hey JA.
    J Pharmacol Exp Ther; 2007 Aug 23; 322(2):486-93. PubMed ID: 17496165
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of interleukin-8 (CXCL8/IL-8) responses by repertaxin, a new inhibitor of the chemokine receptors CXCR1 and CXCR2.
    Casilli F, Bianchini A, Gloaguen I, Biordi L, Alesse E, Festuccia C, Cavalieri B, Strippoli R, Cervellera MN, Di Bitondo R, Ferretti E, Mainiero F, Bizzarri C, Colotta F, Bertini R.
    Biochem Pharmacol; 2005 Feb 01; 69(3):385-94. PubMed ID: 15652230
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.